Vaccine compositions for mucosal delivery

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 6562352
SERIAL NO

08963129

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The invention provides the use of an antigen which is a mucosally immunogenically active substance comprising the 50 kD C fragment of tetanus toxin, an immunogenic fragment thereof, or a derivative thereof formed by amino acid deletion, substitution or insertion for the manufacture of a vaccine composition for administration to a mucosal surface to induce an immune response in the mucosal surface against tetanus infection. The Vaccine composition preferably contains the P.69 outer membrane protein of B. pertussis, and B. pertussis filamentous haemaglutiuin. The invention also provides vaccine compositions per se and a method of treating tetanus and optionally whooping cough using the vaccine compositions.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
MEDEVA HOLDINGS B VAMSTERDAM AMSTERDAM NORTH HOLLAND

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Dougan, Gordon London, GB 26 138
Roberts, Mark London, GB 66 1110

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation